Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 12/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 7/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749992 | 0.91 | HTR2A (0.47) | HTR2AHTR7DRD2HTR1A | |
| SCHEMBL6751049 | 0.86 | HTR2A (0.45) | HTR2AHTR7DRD2HTR1AHTR6 | |
| SCHEMBL6748947 | 0.83 | ABCC1 (0.47) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL6748944 | 0.83 | HTR2A (0.46) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL6747931 | 0.82 | HTR2A (0.49) | HTR2AHTR7DRD2HTR1AHTR6 | |
| SCHEMBL6746150 | 0.82 | HTR2A (0.46) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL6744885 | 0.81 | HTR2A (0.46) | HTR2AHTR7DRD2HTR1A | |
| SCHEMBL6745309 | 0.81 | DRD2 (0.44) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL6748922 | 0.80 | HTR2A (0.46) | HTR2AHTR7DRD2HTR1AHTR6 | |
| SCHEMBL6220399 | 0.75 | HTR2A (0.51) | HTR2AHTR7DRD2HTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | HTR2A 16/4885HTR7 119/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.